Welcome to the ValueWiki PFIZER INC (PFE) article! Register for free or click the "edit" link to contribute!    

PFIZER INC (PFE)

From ValueWiki

Jump to: navigation, search

Pfizer (PFE) is a world class pharmaceutical company that develops and manufactures leading prescription medicines. It is most known for being the maker of Viagra, Lipitor, and Zyrtec.

Contents

Today 5d 3m 6m 1y 2y 5y Max



Funds w/ PFE: 2230
Rank: 8 / 351



[edit]

Company Analysis

Pfizer's leading drug patents include the following:

  • Lipitor - The most widely used treatment for lowering cholesterol, with revenue of about US$ 12 billion annually. Lipitor's has patent protection until 2010 in US[1] and 2011 in most of Europe[2]. An Indian pharmaceuticals company, Ranbaxy, has been challenging Lipitor's patent worldwide in its quest to launch generic version of Lipitor earlier. As of march 2007, ,most courts have mostly upheld Pfizer's patent right till 2010/2011. [1][2]
However, one of Lipitor's main competition, Merck's(MRK) Zocor and Bristol Myers Squibb' (BMY) Pravachol has lost its patent protection in 2006. Several companies like Ranbaxy, Dr. Reddy of India and Teva (TEVA)of Israel are currently producing generic version of Simvastatin (Zocor). [3] This will have some competitive and pricing pressure for Lipitor.


  • Norvasc - World's most-prescribed branded medicine for treating hypertension.
  • Exubera - The first inhaled human insulin therapy, developed under collaboration with Nektar Therapeutic (NKTR). As part of agreement with Pfizer, Nektar receives royalties on sales of Exubera by Pfizer and revenue for the manufacture of the insulin powder and the Exubera Inhalers.[4]
  • Geodon/Zeldox - An anti-psychotic medication for the treatment of schizophrenia and acute manic or mixed episodes associated with bipolar disorder.
  • Lyrica - Relieves two of the most common types of nerve pain: Diabetic Nerve Pain and Pain after Shingles. Lyrica is also approved to treat partial onset seizures in adults with epilepsy who take one or more anti-seizure medicines.
  • Celebrex - Approved to treat the joint pain, stiffness, and swelling of osteoarthritis and adult rheumatoid arthritis.
  • Eraxis - An antifungal approved to treat candidemia, the most deadly of the common hospital-acquired bloodstream infections, and other forms of Candida infections.
  • Sutent - The drug is currently approved to treat two types of cancer, an advanced form of kidney cancer and a cancer of the stomach and intestines called gastrointestinal stromal tumor (GIST) and is currently in Phase II/III clinical trials for other types of cancer. [5] Sutent was developed by Sugen, a South San Francisco biotechnology company focused on kinase inhibitors in oncology. Sugen was acquired by Pharmacia and Upjohn in 1999 for $650 million, and later merged into Pfizer in 2003. Pfizer continued Phase III trials and registration and marketing of the drug. [6][7]
  • Xalatan/Xalacom - A drug used to lower the intraocular pressure associated with glaucoma and ocular hypertension.
  • Zyrtec - The most prescribed antihistamine in the U.S. for seasonal and year-round allergies and hives with once-daily dosing.
  • Chantix/Champix - A prescription treatment for smoking cessation that became available to patients in the U.S. in August 2006.
  • Viagra - The leading treatment for erectile dysfunction and one of the world�s most recognized pharmaceutical brands.

This list is only a sampling of Pfizer's drug patents. In addition to having the protection of patents, several of the above names have very recognizable brands. I am sure you've likely seen advertisements and product placements for Viagra, Zyrtec, and maybe even Lipitor. Pfizer has a very impressive drug marketing capability.

Pfizer also has an animal health business line. Pfizer produces Draxxin for treatment of respiratory disease in cattle and swine. The company also produces Rimadyl for treatment of pain and inflammation associated with canine osteoarthritis and soft-tissue orthopedic surgery. In addition, Pfizer produces Revolution, a parasiticide for dogs and cats.

A detailed intrinsic valuation of Pfizer is provided at Pfizer Price Check.

[edit]

Revenue Highlights [8]

                       SEGMENT/PRODUCT REVENUES
                          TWELVE MONTHS 2006
                        (millions of dollars)

                   WORLDWIDE                U.S.         INTERNATIONAL
                              %                     %                  %
              2006    2005   Chg    2006   2005    Chg  2006   2005   Chg
TOTAL
REVENUES     48,371  47,405    2   25,822 24,751    4  22,549 22,654    -

PHARMA-
CEUTICAL     45,083  44,269    2   24,503 23,471    4  20,580 20,798   (1)

* CARDIOVASCULAR
  AND
  METABOLIC
  DISEASES   19,871  18,732    6   11,124 10,036   11   8,747  8,696    1

  LIPITOR    12,886  12,187    6    7,849  7,401    6   5,037  4,786    5
  NORVASC     4,866   4,706    3    2,500  2,222   13   2,366  2,484   (5)
  CARDURA       538     586   (8)       7      7    -     531    579   (8)
  CADUET        370     185   99      349    179   95      21      6  241
  ACCUPRIL/
  ACCURETIC     266     294  (10)      29     22   37     237    272  (13)
  CHANTIX/
  CHAMPIX       101       -    *      101      -    *       -      -    *

* CENTRAL
  NERVOUS
  SYSTEM
  DISORDERS   6,038   6,391   (6)   3,635  3,816   (5)  2,403  2,575   (7)

  ZOLOFT      2,110   3,256  (35)   1,752  2,573  (32)    358    683  (47)
  LYRICA      1,156     291  297      717    111   M+     439    180  144
  GEODON/
  ZELDOX        758     589   29      631    483   31     127    106   20
  NEURONTIN     496     639  (22)      91    159  (43)    405    480  (16)
  ARICEPT**     358     346    4        1      -    *     357    346    4
  XANAX/XR      316     409  (23)      70    141  (50)    246    268   (8)
  RELPAX        286     233   23      185    143   30     101     90   11

* ARTHRITIS
  AND PAIN    2,711   2,386   14    1,781  1,377   29     930  1,009   (8)

  CELEBREX    2,039   1,730   18    1,577  1,267   24     462    463    -

* INFECTIOUS
  AND
  RESPIRATORY
  DISEASES    3,474   4,770  (27)   1,222  2,449  (50)  2,252  2,321   (3)

  ZYVOX         782     618   27      527    438   20     255    180   42
  ZITHROMAX/
  ZMAX          638   2,025  (69)     210  1,497  (86)    428    528  (19)
  VFEND         515     397   30      178    140   27     337    257   31
  DIFLUCAN      435     498  (13)     (17)   (17)  (3)    452    515  (12)

* UROLOGY     2,809   2,684    5    1,586  1,497    6   1,223  1,187    3

  VIAGRA      1,657   1,645    1      796    802   (1)    861    843    2
  DETROL/
  DETROL LA   1,100     988   11      769    675   14     331    313    5

* ONCOLOGY    2,191   1,996   10      887    701   26   1,304  1,295    1

  CAMPTOSAR     903     910    -      491    471    4     412    439   (6)
  ELLENCE       312     367  (15)      54     73  (26)    258    294  (12)
  AROMASIN      320     247   30      113     85   34     207    162   27
  SUTENT        219       -    *      167      -    *      52      -    *

* OPHTHAL-
  MOLOGY      1,461   1,373    6      483    432   12     978    941    4

  XALATAN/
  XALACOM     1,453   1,372    6      483    432   12     970    940    3

* ENDOCRINE
  DISORDERS     985   1,049   (6)     258    341  (24)    727    708    3

  GENOTROPIN    795     808   (2)     230    239   (4)    565    569   (1)

* ALL OTHER   4,169   3,823    9    2,711  2,205   23   1,458  1,618  (10)

  ZYRTEC/
  ZYRTEC D    1,569   1,362   15    1,569  1,362   15       -      -    *

* ALLIANCE
  REVENUE
  (Aricept,
  Macugen,
  Mirapex,
  Olmetec,
  Rebif and
  Spiriva)    1,374   1,065   29      816    617   32     558    448   25

ANIMAL
HEALTH        2,311   2,206    5    1,032    993    4   1,279  1,213    5

OTHER ***       977     930    5      287    287    -     690    643    7



 *   - Calculation not meaningful.
 **  - Represents direct sales under license agreement with Eisai Co.,
       Ltd.
 *** - Includes Capsugel and Pfizer CenterSource.

 M+  - Change greater than one-thousand percent.
 Certain amounts and percentages may reflect rounding adjustments.
 Certain prior year data have been reclassified to conform to the current
 year presentation.
[edit]

News Feed

09/08/08 7:09 am Pfizer Tries Again With Osteoporosis Drug Fablyn (at The Wall Street Journal Online)
09/08/08 7:09 am Medarex Receives Milestone Payment from Pfizer for Investigational New Drug Application Filing (PR Newswire)
09/08/08 5:09 am Congress likely to delay health care overhaul (AP)
09/08/08 2:09 am 5 Big Pharma Cash Machines (at Seeking Alpha)
09/07/08 7:09 pm Pfizer to Pitch Treatment For Osteoporosis to FDA Panel (at The Wall Street Journal Online)
09/06/08 2:09 pm Taking Aim at Brain Cancer (at Forbes.com)
09/06/08 7:09 am One Outrageously Cheap Stock (at Motley Fool)
09/05/08 6:09 pm India Pharma Ranbaxy Fights FDA Charges (at BusinessWeek)
09/05/08 5:09 pm Final Glance: Pharmaceuticals companies (AP)
09/05/08 3:09 pm 5 Stocks Blasting Off (at Motley Fool)
More News...
[edit]

Risks

This section needs content! Click the blue edit link (to the right) to contribute.

[edit]

Research Links

PFIZER INC in Blogs
PFIZER INC Snapshot
PFIZER INC Leadership
PFIZER INC Fundamentals
PFIZER INC Technical Analysis
[edit]

Message Boards

[edit]

Options

[edit]

Notes

  1. ↑ 1.0 1.1 "U.S. Appeals Court Denies Ranbaxy Petition for Rehearing Regarding Main Patent in Lipitor Case," Company Press Release, October 23, 2006. Accessed March 6, 2007.
  2. ↑ 2.0 2.1 "European Patent Office Supports Validity of Lipitor Patent," Company press release, October 27, 2006. Accessed, march 6 2007.
  3. ↑ Wikipedia article on Simvastatin, Accessed March 06, 2007.
  4. ↑ Exubera page from Nektar corporate website. Accessed on March 14, 2007.
  5. ↑ Pfizer's Pipeline form company website. Accessed, March 6, 2007.
  6. ↑ Wikipedia article on Sunitinib. Accessed on March 6, 2007
  7. ↑ Form 8-K filed by Sugen, Inc. on June 15, 1999. Accessed on March 6, 2007
  8. ↑ "Pfizer Achieves Key 2006 Financial Targets," Company press release, January 22, 2006. Accessed, March 6, 2007.
Retrieved from "http://www.valuewiki.com/w/PFIZER_INC_%28PFE%29"
Personal tools